Metropolitan Life Insurance CO Kinnate Biopharma Inc. Transaction History

Metropolitan Life Insurance CO

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.46 - $7.98 $771 - $1,779	-223 Reduced 11.11%	1,785 $11,000
Q4 2022 Jun 14, 2023	BUY	$5.26 - $12.19 $1,172 - $2,718	223 Added 12.49%	2,008 $12.2 Million
Q4 2022 Mar 30, 2023	BUY	$5.26 - $12.19 $820 - $1,901	156 Added 8.42%	2,008 $12,000
Q4 2022 Feb 15, 2023	BUY	$5.26 - $12.19 $820 - $1,901	156 Added 8.42%	2,008 $12,000
Q3 2022 Jun 14, 2023	BUY	$9.86 - $15.76 $660 - $1,055	67 Added 3.75%	1,852 $22.1 Million
Q2 2022 Jun 20, 2023	BUY	$7.43 - $13.0 $497 - $871	67 Added 3.75%	1,852 $23,000
Q1 2022 Jun 20, 2023	BUY	$7.73 - $17.99 $517 - $1,205	67 Added 3.75%	1,852 $20,000
Q1 2022 Mar 30, 2023	SELL	$7.73 - $17.99 $43,736 - $101,787	-5,658 Reduced 75.34%	1,852 $20,000
Q1 2022 May 12, 2022	SELL	$7.73 - $17.99 $43,736 - $101,787	-5,658 Reduced 75.34%	1,852 $21,000
Q4 2021 Jun 21, 2023	BUY	$16.5 - $25.48 $94,462 - $145,873	5,725 Added 320.73%	7,510 $133,000
Q3 2021 Jun 21, 2023	BUY	$17.81 - $24.87 $101,962 - $142,380	5,725 Added 320.73%	7,510 $172,000
Q3 2021 Mar 30, 2023	BUY	$17.81 - $24.87 $50,170 - $70,058	2,817 Added 60.03%	7,510 $172,000
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $133,753 - $186,773	7,510 New	7,510 $173,000
Q2 2021 Aug 16, 2021	SELL	$22.19 - $31.55 $110 - $157	-5 Closed	0 $0
Q1 2021 Jun 26, 2023	BUY	$26.99 - $40.0 $78,486 - $116,320	2,908 Added 162.91%	4,693 $146 Million
Q1 2021 Mar 30, 2023	BUY	$26.99 - $40.0 $72,468 - $107,400	2,685 Added 133.72%	4,693 $146,000
Q1 2021 May 14, 2021	BUY	$26.99 - $40.0 $134 - $200	5 New	5 $146,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.